SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
TITAN PHARMACEUTICAL (TTP)
An SI Board Since February 1997
Posts SubjectMarks Bans Symbol
362 31 0 TTP
Emcee:  matt wolf Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
312Now a director has been buying some shares from the market. Hubert Huckel boughIcebrg-10/26/2005
311Antipsychotic Drug Stabilization Period For Long-Term Studies Can Be Short, VandIcebrg-10/22/2005
310Good point. A bit cynical, but an increased capacity for cynicism appears to be tom pope-10/21/2005
309If that was indeed the case, I think we would see a lot more insider buying in tIcebrg-10/21/2005
308Here's an angle I'd never considered - from the YMB (not that I think ittom pope-10/21/2005
307And even more insider activity. Robert Farrel CFO has bought 24.000 shares at prIcebrg-10/17/2005
306That was of course meant as a compliment. I could suggest much worse ways of chaIcebrg-10/10/2005
305>that snake< Wasn't there a post somewhere today recounting the dangetom pope-10/10/2005
304More insider activity. CEO and Chairman Louis Bucalo (that snake) has filed for Icebrg-10/10/2005
303Well, Richard Allen was the founder of Theracell, and developed the Spheramine pNeuroInvestment-10/4/2005
302Richard C Allen, Executive Vice President and an employee since 1995, was granteIcebrg-10/4/2005
301I think the idea that Iloperidone can be resuscitated via a genetic test for preDewDiligence_on_SI-1/24/2005
300Vanda seeks to give failed drugs a second chance Mon Jan 24, 2005 01:40 PM ET ByIcebrg-1/24/2005
299Titan Initiates Randomized, Double Blind, Placebo Controlled Phase II Clinical SIcebrg-12/14/2004
298At one time past they got support from Novartis and JJ but as I heard it both coAlfred W. Post-11/10/2004
297Main question with TTP is whether it can monetize its interesting pipeline befortom pope-11/10/2004
296Just to judge by the chart, this seems not have excited any investor. Or does thAlfred W. Post-11/10/2004
295Titan Announces FDA Grants Fast Track Designation for Spheramine(R) for ParkinsoIcebrg-7/12/2004
294Titan Halts Phase II Studies Of Pivanex In NSCL Cancer By Aaron Lorenzo SeniorIcebrg-6/22/2004
293Thanks, Erik, that answers my question more than adequately.tom pope-6/22/2004
292>>Was it something that could have been foreseen (i.e., management blew itIcebrg-6/22/2004
291I've been puzzling over that also. Was it something that could have been fortom pope-6/22/2004
290How unfortunate! They are always surprised by "something"??? Why they Miljenko Zuanic-6/21/2004
289Never a dull day in biotech, it seems. This was unexpected, though. I thought thIcebrg-6/21/2004
288OOOOF: <I>NEW YORK, June 21 (Reuters) - Titan Pharmaceuticals Inc. (AMEX:tom pope-6/21/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News